A Phase Ib/II Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination With Systemic Anti-cancer Agents in Patients With ER Positive Breast Cancer or Advanced Solid Tumors
Latest Information Update: 30 Nov 2023
At a glance
- Drugs Lisaftoclax (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 27 Nov 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 27 Nov 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 12 Aug 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.